Introduction: Cardiac resynchronization using a left ventricular (LV) epicardial lead placed in the coronary sinus is now routinely used in the management of heart failure patients. LV endocardial pacing is an alternative when this is not feasible, with outcomes data sparse.
INTRODUCTION
Cardiac resynchronization therapy (CRT), by placement of an epicardial left ventricular (LV) lead in coronary sinus (CS) has now become a routine procedure to improve symptoms and reduce mortality in patients with advanced heart failure, wide QRS, and a LV ejection fraction (LVEF) less than 35%. [1] [2] [3] Implanting a CRT device may not be possible in approximately 2.5-10% of patients due to inability to access CS, unstable lead position, or unsuitable distal lead position 4, 5 phrenic capture. A further problem is nonresponse to CRT, occurring in up to one-third of patients. 6 Patients in whom implantation of an LV lead in the CS fails can be paced on the LV epicardium using a surgical approach with thoracoscopy or a thoracotomy. 7 Insertion of a transvenous LV endocardial lead has recently been employed as an approach for improving response to CRT and addressing the needs of patients with a failed CS lead implant. 8 Knowledge on the effectiveness and safety of this therapy is sparse, with an increased risk of stroke thought likely. We performed a systematic review and meta-analysis to address this matter.
METHODS

Study selection
We undertook searches on MEDLINE (via PubMED), EMBASE, clinicaltrials.gov, and COCHRANE databases (from inception to September 30, 2017) using the following search string: ("endocardial biventricular pacing" or "endocardial cardiac resynchronisation" or "left ventricular endocardial" or "endocardial left ventricular").
Reference lists of all accessed articles were further searched for sources of potentially relevant information. Authors of full-text papers and congress abstracts were also contacted by e-mail to retrieve additional information.
Only longitudinal studies performed in humans were considered for inclusion. The population, intervention, comparison, and outcome (PICO) approach was used. 9 The population of interest included patients with advanced heart failure and the intervention was CRT implantation, with a LV endocardial lead. The patients acted as their own controls, and the comparison was pre-and postprocedure. LVEF, QRS width, and New York Heart Association (NYHA) functional class at last follow-up were the outcomes. Data on procedural complications and long-term follow-up complications including stroke and infection were also collected.
Additional inclusion criteria were: ≥ five patients in the study, method of anticoagulation stated, LV implantation method described, and presence of follow-up regarding any of the prespecified endpoints.
Minimum follow-up duration was 2 months.
Studies including a mixture of LV endocardial and epicardial leads without individually reported data for each group (and thus, not allowing assessment of LV endocardial lead outcomes), and cross-sectional studies without follow-up were not considered appropriate for inclusion.
Three independent reviewers (AG, SH, and RP) screened all abstracts and titles to identify potentially eligible studies. The full text of these potentially eligible studies was then evaluated to determine the eligibility of the study for the review and meta-analysis. Agreement of at least two reviewers was required for decisions regarding inclusion or exclusion of studies. Study quality was formally evaluated using the National Heart, Lung, and Blood Institute Quality Assessment Tool for Case Series Studies 10 by three reviewers (AG, SH, and RP). An agreement, between the three reviewers, was mandatory for the final classification of studies.
Data extraction and presentation for the preparation of this manuscript followed the recommendations of the PRISMA group. 11 The following data were extracted for characterizing each patient sample in the selected studies, whenever available: age, follow-up duration, anticoagulation regime, gender, % ischemic cardiomyopathy, QRS width pre and post, LVEF pre and post, NYHA class pre and post, fluoroscopy time, procedure time, lead composition, transseptal puncture technique, venous access (femoral vein, internal jugular vein, subclavian vein, others), procedural success, complications, and death during follow-up.
Statistical analysis
Data were pooled using random-effects, as per the Mantel-Haenszel model, through Comprehensive Meta-analysis software (Version 2).
The mean difference (MD) and respective 95% confidence intervals (95% CI) were used as a measurement of treatment effect.
Comparisons were performed for the endpoints: LVEF and NYHA class.
Incidence (with 95% CI) of procedural and long-term complications was assessed. Assessed procedural complications were pneumothorax, cardiac tamponade, stroke (< 1 week of procedure), lead dislodgement (during index procedure admission), pocket hematoma, major bleeding, and complications occurring during follow-up (following discharge after the index procedure) were infection, transient ischemic attack, stroke, and late lead displacement.
As concerns exist regarding an increased risk of postimplant stroke in this population, sensitivity analyses were performed to assess the impact of study design, lead composition (silicone vs polyurethane), access site for left-sided crossing (femoral vs internal jugular vein), and access to LV (interatrial septum vs interventricular septum).
Statistical heterogeneity on each outcome of interest was assessed and quantified using the Cochran Q test and the I 2 statistic, respectively. The I 2 statistic describes the percentage of total variation across studies due to heterogeneity rather than chance. Values of less than 25%, 25-50%, and greater than 50% are by convention classified low, moderate, and high degrees of heterogeneity, respectively. Funnel plots were obtained using the Comprehensive MetaAnalysis software (Version 2) for evaluating the presence of publication bias and traced for comparisons including more than 10 studies (minimum number for ensuring the appropriateness of the method). 12 
RESULTS
Search results
See Figure 1 for the search results.
Study design and population
Baseline data and the design of selected trials are summarized in Table 1 . A total of 362 patients undergoing endocardial LV lead implantation were included. All studies were observational nonrandomized, and had no control groups. Two studies were multicenter, 8 Most studies utilized the interatrial septum to access the left side of the heart, 8, [13] [14] [15] [16] [17] [18] [19] 21, [23] [24] [25] with the interventricular septum used two in studies, 20, 26 with the subclavian vein used to access the septum and deliver the lead. Three studies used an LV apical approach, via a thoracotomy, to deliver the lead to the endocardium. 13, 22, 26 Equipment used to puncture interatrial septum ranged from standard Mullens sheath and Brockenbrough needle, 14, 15, 18 Mullens sheath and Endrys needle, 21 SL-1 sheath with transeptal needle, 17 St.
Jude Agilis 23 to radiofrequency needle. 8, 16, 25 To puncture the interventricular septum, Brockenbrough needle 20 (Betts) , radiofrequency needle, 20 or radiofrequency via a guidewire 20, 26 were used.
The venous access for puncture was femoral, 8, 13, 14, [16] [17] [18] [19] 21, 23, 24 internal jugular, 14, 15 or subclavian/axillary/left pectoral vein. 8, 25 Lead delivery was via the subclavian vein 8, 13, 16, 17, 19, 21, 23, 24 in most cases, with one group using the femoral vein for both lead delivery and interatrial septal access 18 and others used the right internal jugular. 14, 15 Active leads were used in all but one of the studies that specified lead type. Lead material was either polyurethane, 8, 16, 19, 20, 23, 25 silicon, 14, 15, 17, 18, 21 or a combination of the two. 13, 22 Polyurethane leads were thinner (4.1-Fr in all reporting studies, except for 10 patients in Rademakers et al. with 5.7-Fr polyurethane leads). 8, 13, 16, 19, 23 Silicon leads were usually 6-Fr or thicker. 14, 15, 18, 21 Information on techniques employed is shown in the Supplementary Material.
Mean procedure duration was 124 minutes (95% CI 96-151), and the use of fluoroscopy was 28 minutes (95% CI 15-42) in average per case. The overall success rate of LV lead delivery was 98.1%.
Safety
There was one periprocedural death (0.28%), one periprocedural stroke, (0.28%) one pneumothorax (0.28%), and two (0.55%) cases of cardiac tamponade/effusion. The most common periprocedural complication was pocket hematoma, which occurred in 13 (3.65%).
Stroke occurred during follow-up in 17 patients (4.7%), 2.60 per 100 patient-years (95% CI 1.56-4.07), with the study from Rademakers et al. 13 having a higher proportion of strokes (13.7%), 5.88 per 100 patient-years. All patients with ischemic events in that study had a subtherapeutic international normalized ratio (INR) at the time. Devicerelated infections occurred in 13 patients (3.6%) with an incidence of two per 100 patient-years (95% CI 01.1-3.3), and similar numbers were observed for late lead dislodgement (Supplementary Material).
Outcomes
Mean follow-up was 22.3 ± 19.2 months: minimum: 7.6 ± 4.6, maximum: 40 ± 24 months. Three (0.84%) patients were transplanted (0.5 per 100 patient-years, 95% CI 0.1-1.3) with death occurring in 72 (19.9%) (11 per 100 patient-years, 95% CI 13.3-19.5).
The pooling of all study results reveals a reduction in QRS width (MD: -41% 95% CI -75 to -7%; P < 0.0001; I 2 = 94% [Supplemen-
tary Material]). Improvements were demonstrated in NYHA class (MD: -1.06, 95% CI -1.2 to -0.9, P < 0.0001; I 2 = 60%), LVEF (MD 7.9%, 95%
CI 5-10%, P < 0.0001; I 2 = 73%) following endocardial LV lead implantation ( Figure 2 ).
The funnel-plot on NYHA change following implant (only comparison with more than 10 included studies) shows the presence of a mild degree of publication bias (with >5% of studies being outside the 95% CI limit) (Supplementary Material).
Sensitivity analyses for stroke during follow-up
Analysis of data only from full-text papers and multicenter studies yield values as high as 3.7 per 100 patient-years (Table 2) 
Full text paper 
TA B L E 2 Sensitivity analyses for the endpoint stroke during follow-up
Sensitivity analysis N studies FUP (patient-years) Total patients Events
Incidence per 100 patient-years 95% CI favorable data, with an incidence close to of 1.68 and 0 per 100 patientyears. Therefore, analysis of more rigorously scrutinized data showed that the incidence of stroke during follow-up is higher than suggested in the overall pooling of data.
Interventricular septum access was associated with no strokes.
However, a high incidence was observed with the transapical approach.
When pooling studies per the composition of the LV lead, among the nine studies providing this information, the incidence of 
DISCUSSION
LV endocardial pacing reduces QRS duration, and improves LVEF and NYHA, suggesting that it can be an alternative for failed CS lead implants. However, its effect on mortality remains to be assessed in randomized controlled studies. Importantly, the safety profile of LV endocardial leads is not entirely reassuring and some questions merit future consideration, namely, the long-term risk of stroke.
With no controlled studies using LV endocardial leads available, the quality of the data used in this meta-analysis is low. Studies were typically single-center case series, with only two multicenter. There was heterogeneity in the implant procedures, in terms of site used to access the left ventricle and techniques employed to do so. Furthermore, baseline characteristics of the population, such as QRS width and LV, were not clearly defined in some studies 16, 19 and there was interstudy variability. Prevalence of atrial fibrillation was not documented in six studies 16, [22] [23] [24] [25] and CHADSVASC score was not included in any study, although many of them preceded its inception.
LV endocardial pacing has been shown to result in superior hemodynamics, when compared to epicardial pacing, 27 and permits LV electrical mapping, aiding selection of the optimal lead placement site, thus reducing risk of phrenic nerve capture. 18 This contrasts with CS implants often being limited by anatomical constraints. Furthermore, it has been shown to be associated with better LV systolic performance and LV filling characteristics. 28 Pacing the epicardium may be linked to arrhythmia via QT prolongation caused by the reversal of electrical activation. 29 One patient in the Moriña-Vázquez 18 study was reported to have had a marked reduction in ventricular arrhythmias with endocardial pacing. A physiologically appealing explanation for this being the restoration of the natural electrical excitation pattern engaging the endocardial Purkinje network. 18 
Thromboembolic risk
Thromboembolic events in up to a third of patients have been reported with inadvertent endocardial placement of LV leads. 30 The high rates of stroke observed in some studies 8, 13 are particularly concerning, with Rademakers et al. finding 5.88 strokes per 100 patient-years.
The author postulated this could be due to the higher number of NYHA class 4 patients in the study and subtherapeutic INR values.
Without standard biventricular pacing controls, these data are difficult to interpret. The overall incidence of stroke in this meta-analysis was 2.6 per 100 patient-years (95% CI 1.56-4.07), with an overall stroke rate of 4.7% during follow-up. In the sensitivity analyses, it was even higher at 3.29-4.2 per 100 patient-years. This is of relevance, as this analysis included larger studies with better quality outcomes data. 8, [13] [14] [15] [16] [17] [18] [19] [20] [21] 31 These findings are contrary to those of Gamble 32 in a recent meta-analysis of this subject. They reported a stroke risk of 2.5
per 100 patient-years and compared this to the 1.5 per 100 patientyears rate quoted in the SAVE trial, 33 and 0.84 per 100 patient-years in the WARCEF trial, 34 concluding that their results were not statistically different from these similar heart failure cohorts. Comparing our results to the SAVE and WARCEF trials shows a significantly increased risk of stroke (P ≤ 0.05). This may be due to underreporting in case reports and small cohorts of patients (<five patients) without systematic follow-up in the Gamble meta-analysis. Importantly, this means that the reassuring message from this paper is misleading. Thus, in comparison to WARCEF data our cohort have 3-4 times higher rate of stroke. 
Lead materials
The types of leads employed were primarily polyurethane or silicone based. Polyurethane leads theoretically offer a reduction in the risk of thromboembolism and thin leads may reduce the risk of complications with MV. 7 Even though a study in dogs in the 1990s suggested that thrombogenicity with polyurethane leads may be lower, 36 we have observed a comparable incidence of stroke in patients implanted with polyurethane and silicone leads (3.84 and 4.18 per 100 patient-years).
Polyurethane leads are thinner and therefore may also reduce the risk of complications with the MV. 7 The incidence of these complications was so low that we could not observe any differences between the two lead compositions.
Infection
Infective endocarditis is a recognized complication with standard right-sided pacing devices, with pulmonary embolism a known sequela.
The risks associated with MV infection due to a left-sided lead are higher, with cerebrovascular accidents, cerebral abscesses, and renal abscess associated with a high mortality and morbidity. This metaanalysis has shown higher infection rates of two per 100 patient years (13 patients, 3.6%), when compared to standard CRT (1.0%). 4 Although other studies have shown infection rates as high as 4.8%, 37 it is plausible to hypothesize that this infection risk would be higher. Given the known association between pocket hematomas and infection, with all patients being given intraoperative heparin, it is perhaps surprising that the hematoma rate was only 2.7%. This figure is comparable to the 2-4% rate for patients with no anticoagulation or warfarin therapy. 38 With regards to increased infection risk due to repeat procedures, 2.1% of patients had a lead dislodgement during follow-up and 1.9% suffered from an acute dislodgement. Cumulatively, this compares favorably to a 5.8% prevalence quoted for CS implantation. 4 Another potential problem is the complexity and risk associated with procedures to remove infected LV leads, with current technology poorly adapted for their removal. 7 Although all infected devices were extracted without complication in these studies, we do not know yet what the impact of percutaneously extracting an endocardial LV lead 10 years after its implant would be.
Limitations of technology
The lack of equipment specifically designed for implantation of LV His bundle pacing has been shown to reduce heart failure admission in patients with >60% ventricular pacing when compared to standard RV lead placement. 41 Thus, offering optimism for its potential use as an alternative to CS lead placement. However, results from Bifocal RV pacing show that this technique may be inferior to standard biventricular pacing. 42 Wireless ultrasound-powered endocardial pacing 43 or battery-powered devices 44, 45 offer new alternatives for avoiding leads altogether. These technologies face challenges in terms of additional subcutaneous generator placement for the ultrasound-powered devices and ensuring an optimal acoustic window with stable capture synchronized to an endocardial RV lead versus non-US leadless electrodes that will require stable wireless communication with right-sided standard or leadless systems.
Limitations of study
This meta-analysis is subject to several limitations. First, high heterogeneity among included studies leading to data interpretation being nonlinear. Second, the low quality of studies clearly affects data interpretation, and the positive result of the global analyses should be interpreted very conservatively. Third, as patient-level data were available only for a minority of studies, there is no data on time-to-event for most the assessed outcomes. Therefore, we used total follow-up, which presents the data on the incidence of complications as "a best-case scenario." In fact, had we used time-to-event data, we could expect a 10-20% relative increase in the incidence rate. Even though this is an issue, we believe that our safety data should raise concern regarding this technique, even in this best-case scenario. Last, a randomized controlled trial is still needed in this area comparing the technique to matched epicardial CRT cohort.
CONCLUSION
LV endocardial lead implantation offers an efficacious alternative to traditional CS implantation leading to an improvement in NYHA class, LVEF and QRS duration. However, it is limited by concerns surrounding its safety profile, particularly an increased risk of stroke which we believe has been underestimated in recently published work. Further data with randomized controlled trial or observational case-controls are required before this approach can be recommended to the broad heart failure population.
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